SK pharmteco
John Bowen is a highly experienced professional in the fields of nucleic acids and plasmid operations, currently serving as Senior Director at SK pharmteco since January 2024 and at the Center for Breakthrough Medicines since September 2021. With prior leadership roles as Director of Business Operations and Process Development at the same center and experience as a Senior Scientist at Novartis Gene Therapies, John has a robust background in scientific research and development. Academic qualifications include a Doctor of Philosophy in Chemical Engineering and a Master of Science from North Carolina State University, complemented by a Bachelor of Science in Chemical Engineering from Penn State University. Career highlights also include positions across various organizations such as Merck, Novartis Vaccines and Diagnostics, and Seqirus, showcasing a well-rounded expertise in bioprocess development and scientific consulting.
This person is not in any offices
SK pharmteco
Headquartered in Rancho Cordova, California, SK pharmteco is a global contract development and manufacturing organization specializing in the production of active pharmaceutical ingredients (APIs), advanced intermediates, and cell and gene therapy for the pharmaceutical industry. Built on 80 years of experience, our global operations have the capability and capacity to support client needs from development through commercial production. SK pharmteco is owned by SK Inc., the strategic investment arm of South Korea’s SK Group.